ArticleMedicine2026
A cost-effectiveness analysis of herbal medicine for overweight and obese children.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe number of obese children and the resulting socioeconomic burden are increasing, and herbal medicine is being widely used for overweight and obese children due to the limitations of conventional treatments, such as low compliance with lifestyle interventions. The purpose of this study was to analyze the cost-effectiveness of herbal medicine for overweight and obese children.
methodsBased on the electronic medical records of 3 Korean medicine institutions from January 2012 to February 2023, data from overweight and obese children aged 2 to 19 years who were prescribed herbal medicine for weight loss were analyzed. Effectiveness outcomes were the body mass index percentile and z-score, and direct medical costs, including costs of consultation, examination, and herbal medicines that could be confirmed through medical records, were analyzed. The average cost-effectiveness ratios (ACERs) of herbal medicines were calculated based on the healthcare system perspective.
resultsA total of 183 patients were included in the analysis. After herbal medicine administration for an average of 75.78 days, the ACERs of herbal medicines per 1 body mass index percentile and z-score reduction were 343 United States dollar and 1980 United States dollar, respectively. The ACERs were generally lower among females, those who visited Korean medicine institutions with obesity or overweight as the principal diagnosis, and those prescribed herbal medicine including Ephedra Herba. Furthermore, the ACERs of Gambi-san, Wolbigachul-tang, Joripyewon-tang, and Pyeongjin-tang were generally low.
conclusionHerbal medicine might be a cost-effective weight-loss treatment for overweight and obese children. These findings may inform healthcare providers, policymakers, and patients considering the use of herbal medicine for pediatric obesity management. Further large-scale, long-term controlled clinical studies should be conducted to assess cost-effectiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.